Randomised control trials (RCTs) are a gold standard for research – generally gathering their own data despite the UK’s large, and growing, quantity of routinely collected health data (RCHD). This potentially points to large and expensive duplications of effort. In order to gain insights into the issue, and make recommendations for a way forward, the researchers approached registries to ask how many successful RCHD applications were for RCTs.
A step change is urgently needed so that UK clinical trials can fully harness the power of RCHD to conduct more efficient RCTs. However, there has been little research into the extent to which researchers receive data from registries for use in RCTs. Similarly, little was known about the obstacles limiting its use. Understanding these could point to ways forward.
The researchers, including Prof. Matthew R Sydes (HDR UK associated researcher and Professor of Clinical Trials and Methodology at UCL), asked registries about the number of successful applications they had dealt with to supply data for clinical trials. The work (carried out by a HDR –UK funded researcher at the MRC clinical trials unit at UCL) also identified barriers to the use of RCHD. The findings were published in the journal Trials (by BMC) in May 2020.
Only around 2% of successful applications to those registries were for data for RCTs.
Some 160 trials were identified as successfully accessing RCHD to inform participant data, from 22 UK registries, between 2013 and 2018. Many (47%, 43/91) used it for the primary outcome measure. The researchers estimate this equates to fewer than 5% of RCTs in the UK using RCHD. RCHD use was generally for large trials – commonly those evaluating treatments for cancer or cardiovascular disease.
If the potential of RCHD in RCTs is to be tapped – and a move made towards what Prof Sydes calls a “mixed economy” – then barriers need to be addressed including:
- The need for clear terminology to describe registry data
- Lack of awareness of RCHD availability and utility
- Challenges to data accessibility and retention
- Quality and timeliness
- Regulatory validity of RCHD.
Impact and outcomes
This is believed to be the first review to approach registries in this way and the first to assess the use of these data specifically for trial outcome measure assessment. It has helped fill a significant gap in the literature.
It underscores the value of HDR UK initiatives such as the development of the Innovation Gateway, which endeavours to improve and increase health data access.
Insights from the Impact Committee
The HDR UK Impact Committee chose this paper for its excellence, significance, originality and rigour. In exploring issues around clinical trials it is also addressing one of HDR UK’s national priorities.
EMPA-KIDNEY trial: Effect of empagliflozin on chronic kidney disease progression
7 December 2022
EMPA-KIDNEY is an international clinical trial by Oxford Population Health scientists in collaboration with academics spanning eight countries. The study recruited over 6000 participants to...
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
21 June 2022
A large-scale clinical trial of a monoclonal antibody treatment for COVID-19 showed that it could reduce deaths by 21 per cent in people who had not mounted a natural antibody response of their own.
Clinical trials Day 2022: How data can make trials faster, more efficient and better at improving care
20 May 2022
We explore how routinely collected health data may hold the key to super-charging how clinical trials are delivered, and in turn, how quickly we can bring improvements to people's lives.